Extra-adrenal paraganglioma with isolated localization in the urinary bladder is a rare neuroendocrine tumor. Although the typical symptoms like headache, nausea, weight loss, flushing, heart palpitation or paroxysmal hypertension during micturition are well established, we present an unusual case of bladder paraganglioma, ‘misdiagnosed' with basilar-type migraine due to headache for the past 8 years. As urologists linked the presence of a tumor (by CT) and symptoms connected with micturition, no cystoscopy and no transurethral resection of the bladder was performed prior to detailed diagnostic workup. After diagnosis of an extra-adrenal paraganglioma, the patient was scheduled for open partial cystectomy. In consideration of the fact that bladder paraganglioma is an infrequent genitourinary cancer, this case report clearly points out the importance of an exact anamnesis and clinical examination to minimize the probability of misdiagnosis with possible fatal consequences in any case with clinical suspicion of bladder paraganglioma.

Keywords:
Bladder paraganglioma, Extra-adrenal pheochromocytoma, Basilar-type migraine, Paragangliomas, diagnosis and therapy
1.
Lenders JW, Eisenhofer G, Mannelli M, Pacak K: Phaeochromocytoma. Lancet 2005;366:665-675.
2.
Young WF Jr: Paragangliomas: clinical overview. Ann NY Acad Sci 2006;1073:21-29.
3.
Tazi MF, Ahallal Y, Tazi E, Benlemlih A, Chbani L, Amarti A, El Fassi MJ, Farih MH: Pheochromocytoma of the urinary bladder: a case report. Cases J 2009;2:8585.
4.
Sharabi Y: Phaeochromocytoma: progress and challenges. Isr Med Assoc J 2011;13:304-305.
5.
Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB: The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007;14:569-585.
6.
Lee JH, Barich F, Karnell LH, Robinson RA, Zhen WK, Gantz BJ, Hoffman HT; American College of Surgeons Commission on Cancer; American Cancer Society: National cancer database report on malignant paragangliomas of the head and neck. Cancer 2002;94:730-737.
7.
Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, Pacak K: Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003;88:2656-2666.
8.
Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G: Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002;287:1427-1434.
9.
Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF, Jeunemaitre X; COMETE Network: Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 2003;63:5615-5621.
10.
Cascón A, López-Jiménez E, Landa I, Leskelä S, Leandro-García LJ, Maliszewska A, Letón R, de la Vega L, García-Barcina MJ, Sanabria C, Alvarez-Escolá C, Rodríguez-Antona C, Robledo M: Rationalization of genetic testing in patients with apparently sporadic pheochromocytoma/paraganglioma. Horm Metab Res 2009;41:672-675.
11.
Gimm O, DeMicco C, Perren A, et al: Malignant phaeochromocytomas and paragangliomas: a diagnostic challenge. Langenbecks Arch Surg 2012;397:155-177.
12.
Eisenhofer G, Tischler AS, de Krijger RR: Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. Endocr Pathol 2012;23:4-14.
13.
Poirier E, Thauvette D, Hogue JC: Management of exclusively dopamine-secreting abdominal pheochromocytomas. J Am Coll Surg 2013;216:340-346.
14.
Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, Mannelli M, Linehan WM, Adams K, Timmers HJ, Pacak K: Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 2012;48:1739-1749.
15.
Baez JC, Jagannathan JP, Krajewski K, O'Regan K, Zukotynski K, Kulke M, Ramaiya NH: Pheochromocytoma and paraganglioma: imaging characteristics. Cancer Imaging 2012;12:153-162.
16.
Ilias I, Pacak K: Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 2004;89:479-491.
17.
Kang SG, Kang SH, Choi H, et al: Robot-assisted partial cystectomy of a bladder phaeochromocytoma. Urol Int 2011;87:241-244.
18.
De Pasquale V, Magistrelli A, Diomedi Camassei F, Caione P: Unusual bladder mass in a 14-year-old boy: bladder paraganglioma. Urol Int 2011;86:117-120.
19.
Yang Y, Wei ZT, Lu JS, et al: Transurethral partial cystectomy with 2-μm thulium continuous wave laser in the treatment of bladder phaeochromocytoma. J Endourol 2012;26:686-690.
20.
Kozlowski PM, Mihm F, Winfield HN: Laparoscopic management of bladder phaeochromocytoma. Urology 2011;57:365.
21.
Nerli RB, Reddy M, Koura AC, et al: Cystoscopy-assisted laparoscopic partial cystectomy. J Endourol 2008;22:83-86.
22.
Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Prejbisz A, Timmers H, Plouin PF: Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res 2012;44:385-389.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.